We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
-4.86%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$16B
AUM Growth
-$1.05B
Cap. Flow
-$192M
Cap. Flow %
-1.2%
Top 10 Hldgs %
35.77%
Holding
1,457
New
38
Increased
735
Reduced
275
Closed
40

Sector Composition

Rank Sector Weight
1 Real Estate 60.21%
2 Technology 9.75%
3 Consumer Discretionary 4.32%
4 Healthcare 3.56%
5 Financials 3.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NSTG
1151
DELISTED
NanoString Technologies, Inc.
NSTG
$5K ﹤0.01%
156
CCXI
1152
DELISTED
ChemoCentryx, Inc.
CCXI
$5K ﹤0.01%
204
ALEC icon
1153
Alector
ALEC
$169M
$4K ﹤0.01%
277
ALLO icon
1154
Allogene Therapeutics
ALLO
$625M
$4K ﹤0.01%
416
AMRN
1155
Amarin Corp
AMRN
$297M
$4K ﹤0.01%
67
BBIO icon
1156
BridgeBio Pharma
BBIO
$16.4B
$4K ﹤0.01%
429
CDXS icon
1157
Codexis
CDXS
$158M
$4K ﹤0.01%
189
CSTL icon
1158
Castle Biosciences
CSTL
$742M
$4K ﹤0.01%
86
EDIT icon
1159
Editas Medicine
EDIT
$399M
$4K ﹤0.01%
200
KYNB
1160
Kyntra Bio
KYNB
$27.4M
$4K ﹤0.01%
13
HCM icon
1161
HUTCHMED
HCM
$1.96B
$4K ﹤0.01%
185
-5,526
-97% -$141K
INVA icon
1162
Innoviva
INVA
$1.6B
$4K ﹤0.01%
191
ITOS
1163
DELISTED
iTeos Therapeutics
ITOS
$4K ﹤0.01%
121
KROS icon
1164
Keros Therapeutics
KROS
$197M
$4K ﹤0.01%
80
KURA icon
1165
Kura Oncology
KURA
$793M
$4K ﹤0.01%
227
LYEL icon
1166
Lyell Immunopharma
LYEL
$318M
$4K ﹤0.01%
35
PCVX icon
1167
Vaxcyte
PCVX
$7.65B
$4K ﹤0.01%
179
PTGX icon
1168
Protagonist Therapeutics
PTGX
$8.55B
$4K ﹤0.01%
163
TIL icon
1169
Instil Bio
TIL
$49M
$4K ﹤0.01%
19
XENE icon
1170
Xenon Pharmaceuticals
XENE
$6.1B
$4K ﹤0.01%
141
MORF
1171
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$4K ﹤0.01%
108
NGM
1172
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4K ﹤0.01%
265
RETA
1173
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$4K ﹤0.01%
108
RXDX
1174
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$4K ﹤0.01%
114
TPTX
1175
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$4K ﹤0.01%
144

Similar funds

Daiwa Securities Group's Q1 2022 Portfolio in Review

As of Q1 2022, Daiwa Securities Group held 1,457 positions worth $16B, down 6.2% from $17B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Daiwa Securities Group's Q1 2022 filing shows 38 new, 735 increased, 275 reduced and 40 closed positions. Its largest new stake was Federal Realty Investment Trust: 21,861 shares worth $2.67M. The largest sale was Ventas, an estimated $181M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q1 2022 buy was Federal Realty Investment Trust: 21,861 shares worth $2.67M.
  • Daiwa Securities Group added most to Invitation Homes in Q1 2022, an estimated $216M increase.
  • Daiwa Securities Group's biggest Q1 2022 reduction was Ventas, cutting an estimated $181M.
  • Daiwa Securities Group fully exited Xilinx Inc in Q1 2022, selling an estimated $4.54M.
  • Daiwa Securities Group's ten largest holdings make up 36% of its $16B portfolio in Q1 2022.
  • Daiwa Securities Group opened 38 new positions and closed 40 in Q1 2022.
  • Daiwa Securities Group's portfolio value fell 6.2% quarter-over-quarter to $16B.

Based on Daiwa Securities Group's 13F filing for Q1 2022, filed 29 Apr 2022.